The Age-Related Eye Disease Study 2 (AREDS2) started in 2006 and was completed in 2012. AREDS2 is a second separate study from the original AREDS study. The purpose of this study was to improve and test different combinations of the original AREDS formula by adding omega-3 fatty acids, antioxidants lutein and zeaxanthin, removing beta-carotene, and lowering the amount of zinc. The antioxidants, lutein and zeaxanthin, were added to substitute beta-carotene from the formula because of the risk of lung cancer for smokers and former smokers found in a study conducted by the National Cancer Institute (NCI). Researchers added omega-3 fatty acids because of recent research found that it may be helpful to vision health and the zinc was lowered because some experts believed 80 mg was too high of a dosage.